NBRVF — Nabriva Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Nabriva Therapeutics PLC reports results for the quarter ended in September - Earnings Summary
Brief: Nabriva Therapeutics Posts Q3 Revenue Of $8.9 Million
Nabriva Therapeutics PLC expected to post a loss of 24 cents a share - Earnings Preview
Brief: Nabriva Publishes Data Demonstrating The Potent Anti-Inflammatory Properties Of Xenleta (Lefamulin)
Brief: Nabriva Therapeutics Says Co, Lincoln Park Capital Fund Entered Into Purchase Agreement
Brief: Nabriva And Vizient Enter Into Agreement To Make Xenleta Available To Vizient's Pharmacy Network Program
U.S. STOCKS ON THE MOVE-Ford, Genius Sports, GameStop
U.S. STOCKS ON THE MOVE-Virios, McAfee, Perrigo
Nabriva Therapeutics rises on pneumonia drug approval in Taiwan
Brief: Lefamulin Receives Approval In Taiwan For Treatment Of Community-Acquired Pneumonia
U.S. STOCKS ON THE MOVE-Gannett, FireEye, Novavax Inc
U.S. STOCKS ON THE MOVE-Kaixin Auto, Dicerna Pharma, Yelp
U.S. STOCKS ON THE MOVE-Yelp, GoPro, Switch
U.S. STOCKS ON THE MOVE-AngloGold, Global, Groupon
Nabriva Therapeutics up on Q2 revenue beat
Nabriva Therapeutics PLC reports results for the quarter ended in June - Earnings Summary
Nabriva Therapeutics PLC expected to post a loss of 35 cents a share - Earnings Preview
Brief: Nabriva Therapeutics Says Elected Lisa Dalton And Mark Corrigan As Members Of Board
Brief: Nabriva Agrees To Extension Of Principal Debt Repayments Under Existing Loan Agreement With Hercules Capital